NCT04169022已完成不适用
Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) Expressing Acute Myeloid Leukemic (AML) Cells by Chimeric Antigen Receptor (CAR) Engineered T-cells
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 86
- 试验地点
- 2
- 主要终点
- IL1RAP protein expression
研究概览
简要总结
AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients
Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AML patients adults and pediatrics
排除标准
- 未提供
结局指标
主要结局
IL1RAP protein expression
时间窗: 2 years
Cytometry analysis
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Allo-Allo Tandem Bone Marrow Transplant (BMT)Refractory Acute LeukemiaNCT00984412Hadassah Medical Organization15
已完成
2 期
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for TransplantAcute Myeloid LeukemiaNCT02771197Northside Hospital, Inc.20
撤回
不适用
Interferon-α Prevents Leukemia Relapse of AML Patients After TransplantationInterferon-A-2BRelapsePreventionHematopietic Stem Cell TransplantationNCT03121079Peking University People's Hospital
已完成
不适用
Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)Chronic Myeloid LeukemiaNCT02842320Centre Hospitalier Universitaire de Besancon53
已完成
不适用
Transfusion in Adult Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02899767Hospices Civils de Lyon1,067